ONC1-13B NEW
Price | $293 | $719 | $987 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-20 |
Product Details
Product Name: ONC1-13B | CAS No.: 1351185-54-0 |
Purity: 99.85% | Supply Ability: 10g |
Release date: 2024/11/20 |
Product Introduction
Bioactivity
Name | ONC1-13B |
Description | ONC1-13B is a potent androgen receptor (AR) antagonist with an ic50 in the range of 59-80 nM that inhibits PSA production in androgen-sensitive human PCa LNCaP cells. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Keywords | ONC1 13B | ONC113B | ONC1-13B |
Inhibitors Related | Dehydroisoandrosterone 3-acetate | Bicalutamide | S-23 | Bavdegalutamide | Enzalutamide | Adrenosterone | Allura Red AC | Sunset Yellow FCF | Ostarine | Flutamide |
Related Compound Libraries | Bioactive Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
$40.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-09-19 | |
$0.00/1KG |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-09-29 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY